Assessing the Effectiveness of Hormonal Aromatase inhibitors (AI) Therapy in Hormone Receptor Positive Post-Menopausal Breast Cancer Patients: A Systematic Review
DOI:
https://doi.org/10.71341/bmwj.v1i2.7Keywords:
aromatase inhibitors, breast cancer, postmenopausal, estrogen, progesteroneAbstract
Background: Endocrine therapy is a cornerstone in the treatment of breast cancer for patients who are hormone receptor-positive (HR+). Aromatase Inhibitors are a key option for managing HR+ breast cancer in postmenopausal women.
Objective: This study investigates the efficacy of Aromatase Inhibitors in postmenopausal women with HR+ breast cancer, focusing on their therapeutic benefits and associated risks.
Methods: A comprehensive literature review was conducted using the Cochrane, Google Scholar, PubMed, Science Direct, ClinicalTrials.gov, and Scopus databases, adhering to PRISMA guidelines. Study quality was evaluated using the Risk of Bias for Randomized Trials (RoB 2.0) tool.
Results: Aromatase Inhibitors function by inhibiting the aromatase enzyme, effectively reducing estrogen production. While they can be used with other therapies such as metformin or saracatinib, these combinations are not significantly more effective. Aromatase Inhibitors have been shown to enhance cognitive function and alleviate some depressive symptoms, although they may increase the risk of depression and anxiety in some patients.
Conclusion: Aromatase Inhibitors are an effective treatment for HR+ breast cancer in postmenopausal women. However, the potential psychological side effects, such as depression and anxiety, require careful management during therapy.
References
Aggelis, V., & Johnston, S. R. D. (2019). Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. Drugs, 79(17), 1849–1866. https://doi.org/10.1007/s40265-019-01208-8
Bahrami, N., Chang, G., Kanaya, N., Sauer, T., Park, D., Loeng, M., Gravdehaug, B., Chen, S., & Geisler, J. (2020). Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane. The Journal of Steroid Biochemistry and Molecular Biology, 200, 105641. https://doi.org/10.1016/j.jsbmb.2020.105641
Boszkiewicz, K., Piwowar, A., & Petryszyn, P. (2022). Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients-A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 11(11). https://doi.org/10.3390/jcm11113133
Fitzal, F., Filipits, M., Fesl, C., Rudas, M., Greil, R., Balic, M., Moinfar, F., Herz, W., Dubsky, P., Bartsch, R., Ferree, S., Schaper, C., Gnant, M., & Austrian Breast and Colorectal Cancer Study Group (ABCSG). (2021). PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial. The British Journal of Surgery, 108(3), 308–314. https://doi.org/10.1093/bjs/znaa089
García-Sánchez, J., Mafla-España, M. A., Torregrosa, M. D., & Cauli, O. (2022). Adjuvant aromatase inhibitor treatment worsens depressive symptoms and sleep quality in postmenopausal women with localized breast cancer: A one-year follow-up study. Breast (Edinburgh, Scotland), 66, 310–316. https://doi.org/10.1016/j.breast.2022.11.007
Gnant, M., Fitzal, F., Rinnerthaler, G., Steger, G. G., Greil-Ressler, S., Balic, M., Heck, D., Jakesz, R., Thaler, J., Egle, D., Manfreda, D., Bjelic-Radisic, V., Wieder, U., Singer, C. F., Melbinger-Zeinitzer, E., Haslbauer, F., Sevelda, P., Trapl, H., Wette, V., … Greil, R. (2021). Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. New England Journal of Medicine, 385(5), 395–405. https://doi.org/10.1056/NEJMoa2104162
Krásenská, M. (2016). [Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects]. Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti, 29 Suppl 3, S39-49. https://doi.org/10.14735/amko20163S39
Makkena, A., Appavu, R., & Kethar, J. (2023). Implications of Aromatase Inhibitor Therapy in Postmenopausal Breast Cancer. Journal of Student Research, 12(1). https://doi.org/10.47611/jsrhs.v12i1.4104
Martino, G., Catalano, A., Agostino, R. M., Bellone, F., Morabito, N., Lasco, C. G., Vicario, C. M., Schwarz, P., & Feldt-Rasmussen, U. (2020). Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer. PloS One, 15(3), e0230681. https://doi.org/10.1371/journal.pone.0230681
Mirsyad, A., Gani, A. B., Karim, M., Purnamasari, R., Karsa, N. S., Tanra, A. H., & Julia. (2022). Hubungan Usia Pasien Dengan Tingkat Stadium Kanker Payudara Di RS Ibnu Sina Makassar 2018. Jurnal Mahasiswa Kedokteran, 2(5), 359–367.
Ningrum, M. P., & Rahayu, R. S. R. (2021). Determinan Kejadian Kanker Payudara pada Wanita Usia Subur (15-49 Tahun). Indonesian Journal of Public Health and Nutrition, 1(3), 362–370.
Oswald, A. J., Symeonides, S. N., Wheatley, D., Chan, S., Brunt, A. M., McAdam, K., Schmid, P., Waters, S., Poole, C., Twelves, C., Perren, T., Bartlett, J., Piper, T., Chisholm, E. M., Welsh, M., Hill, R., Hopcroft, L. E. M., Barrett-Lee, P., & Cameron, D. A. (2023). Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment, 199(1), 35–46. https://doi.org/10.1007/s10549-023-06873-8
Peters, A., & Tadi, P. (2023). Aromatase Inhibitors. In StatPearls.
Zhao, Y., Gong, C., Wang, Z., Zhang, J., Wang, L., Zhang, S., Cao, J., Tao, Z., Li, T., Wang, B., & Hu, X. (2017). A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer. Oncotarget, 8(48), 84224–84236. https://doi.org/10.18632/oncotarget.20478
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Angki Perdiyana , Agri Lesmana , Dea Syafira Alamsyah Sitompul , Fakhira Ayu Wijayanti , Miko Dharma Alrasyid , Naufal Yafi Rais Wiguna , Tharisa Novianti Syabania Sutomo , Deity Nugraha, Elies Fitriani
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
License
This work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercial purposes.
- Adaptation — mixing, changing, and developing materials for any purpose, even commercial ones.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
